{"entity":{"id":"nct06585410","kind":"trial","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","aka":[],"tldr":"A phase 3 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.","summary":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06585410 by Regeneron Pharmaceuticals, with 369 participants planned, started 2025-01-02 and due to reach its primary completion in 2030-05-03. Interventions recorded: Cemiplimab, Standard of care. Conditions listed: Cutaneous Squamous Cell Carcinoma (CSCC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06585410","url":"https://clinicaltrials.gov/study/NCT06585410"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cutaneous-scc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06585410","phase":"3","setting":"A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)","sponsor":"Regeneron Pharmaceuticals","participation":[{"nct":"NCT06585410","source":"https://clinicaltrials.gov/study/NCT06585410","fetchedAt":"2026-10-07T16:54:49.791Z","studySha256":"273a11d14580df93f9f9e33bb807bf029316cb3a907103c96aa5d5a8eddcba47","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-16","leadSponsor":"Regeneron Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":369,"enrolmentType":"ESTIMATED","siteCount":53,"recruitingSiteCount":50,"countries":["Australia","United States"]}],"started":"2025-01-02","startedType":"actual","enrolled":369,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06585410/","neighbours":{"cancer":[{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}